IRLAB Therapeutics AB Administers the First Dose in A Phase

IRLAB Therapeutics AB announced that dosing has been initiated in a Phase I study of the drug candidate IRL757. IRL757 has been shown in preclinical disease models to counteract apathy - a condition...

Related Keywords

, Michaelj Fox Foundation , Single Ascending Dose , Multiple Ascending Dose ,